LLY
Eli Lilly and Company
Drug Manufacturers - General · Healthcare · United States
1,373.70
close · 2026-10-29
value
8
cheaper than peers8
quality
91
stronger fundamentals91
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 28.94× | 28 |
| EV to EBITDA | 28.64× | 23 |
| price to sales | 15.38× | 22 |
| price to book | 36.15× | 4 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 54.2% | 99 |
| return on equity | 102.3% | 98 |
| revenue growth | 47.7% | 84 |
| debt to equity | 162.1% | 15 |
4 of 4 measures available
Facts
| market cap | $1.22T |
| free cash flow | $11.07B |
| employees | 50,000 |
| first trade | 1972-06-01 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 22.95 | 11.71 | 5.80 | 6.57 |
| free cash flow | $5.96B | $414.0M | -$3.15B | $4.60B |
| net income | $20.64B | $10.59B | $5.24B | $6.24B |
| revenue | $65.18B | $45.04B | $34.12B | $28.54B |
| unusual items | -$3.39B | -$4.14B | -$3.87B | -$1.56B |